The JAK inhibitor, ruxolitinib, inhibited STAT3 phosphorylation, increased CD38 expression in MM cells, and enhanced the antibody-dependent cellular cytotoxicity (ADCC) function of the anti-CD38 antibody DARA [116]. This evidence concerns the gene STAT3 and Miyoshi myopathy.